On September 24, 2026 Elephas Biosciences Corporation, developer of a functional precision medicine platform for oncology therapy response measurement, reported a collaboration with Italy-based Tes Pharma to evaluate TES-4207, a first-in-class investigational therapy targeting NR2F6 for treatment of non-small cell lung cancer (NSCLC). Through the collaboration, Elephas’ elive platform will characterize functional response to TES-4207 in live human NSCLC tumor tissue, as a monotherapy and in combination therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As Tes Pharma integrates the ex vivo elive platform with their TES-4207 small molecule program, researchers will use functional data from live human NSCLC tumor tissue to characterize response phenotypes and inform continued translational and clinical development. The data will provide additional functional insights to support ongoing evaluation and development of the molecule.
"As we continue advancing TES-4207, understanding functional response in live human tumor tissue provides an important layer of information to support our first-in-class development program," shared Francesco Greco, Project Leader at Tes Pharma. "The insights generated through this collaboration will help us better understand the potential of TES-4207, alone and in combination with other therapies, as we determine the best path forward."
Elephas’ elive platform keeps tumor tissue alive and preserves the native tumor microenvironment, measuring therapeutic response directly rather than inferring it. For pharma partners, this generates functional human response data that can inform mechanism of action, combination therapy evaluation, and responder and non-responder profiling as programs move through translational and clinical development.
"We are pleased to collaborate with Tes Pharma and apply our elive platform to the development of TES-4207," shared Erika von Euw, PhD, MBA, Vice President, Scientific Affairs at Elephas. "Evaluating TES-4207 directly in live tumor tissue, both as a monotherapy and in combination with PD-1 blockade, allows us to capture tissue-specific functional responses while preserving the complexity of the tumor microenvironment. These insights can help inform clinical development and support a more precise approach to identifying groups most likely to benefit."
(Press release, Tes Pharma, SEP 24, 2026, View Source [SID1234671061])